PRAFUL DESAI: Open Payments
NPI 1841383718 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$543 in 24 payments from 9 companies in 2025. Trend: 2023 $326 · 2024 $521 · 2025 $543
Food & beverage: $543
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 8 | $168 |
| Lundbeck LLC | 4 | $92 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $92 |
| Alkermes, Inc. | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $38 |
| ABBVIE INC. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $28 |
| Neurocrine BioSciences, Inc. | 1 | $25 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
Products named: Auvelity, REXULTI, CAPLYTA, INVEGA SUSTENNA, VRAYLAR, HETLIOZ, ARISTADA, INGREZZA.
Industry payments across DE — which companies pay providers there.
